Refine
Document Type
- Doctoral Thesis (5)
Language
- English (5) (remove)
Has Fulltext
- yes (5)
Is part of the Bibliography
- no (5)
Institute
- Medizin (5)
Sepsis is caused by infection and often followed by an overwhelming inflammatory response. This can lead to shock, organ failure and even death. Each year approximately 60,000 people die in Germany due to sepsis. There is good evidence that sepsis is associated with failure of the hypothalamic-pituitary-adrenal-axis. In patients with sepsis, glucocorticoids (e.g. corticosterone, cortisol) released from adrenal glands play an essential role in preventing an excessive pro-inflammatory response. Adrenal insufficiency occurs in a large number of patients with septic shock and is associated with an increased mortality. In the innate immune system, Toll-like receptors (TLRs) play a crucial role in its onset by recognizing pathogenassociated molecules. It is well known that there are interactions between the immune and endocrine stress systems; glucocorticoids and TLRs regulate each other in a bi-directional way. Therefore, a coordinated response of the adrenal and immune system is of vital importance for survival during severe inflammation. This experimental study focuses on the role of TLR-2, TLR-4 and TLR-9 during adrenal stress. The results show that in mice, the absence of TLR-2 and TLR-4, but not TLR-9 leads to altered adrenal morphology, relating to size and cellular structure. However, this alteration does not appear to compromise the phenotype of TLR knock-out mice. Mice deficient of TLR-2, 4 and 9 are not able to respond adequately to inflammatory stress induced by their potential ligands lipopolysaccharide (LPS), lipoteichoic acid (LTA) or cytidine phosphate guanosine-oligodeoxynucleotides (CpG-ODN). This impaired adrenal stress response appears to be associated with a decrease in systemic and intra-adrenal cytokine expressions. Taken together, these results suggest that TLR-2, 4 and 9 are key players in the immuno-endocrine response during inflammation and SIRS. In conclusion, TLRs play a crucial role in the immune-adrenal crosstalk. This close functional relationship needs to be considered in the treatment of inflammatory diseases where an intact adrenal stress response is required. Furthermore, TLR polymorphisms could contribute to the underlying mechanisms of impaired adrenal stress response in patients with bacterial sepsis
Despite sensible guidelines for the use of opioid analgesics, respiratory depression remains a significant risk with a possibility of fatal outcomes. Clinicians need to find a balance of analgesia with manageable respiratory effects. The ampakine CX717 (Cortex Pharmaceuticals, Irvine, CA, USA), an allosteric enhancer of glutamate-stimulated AMPA receptor activation, has been shown to counteract opioid-induced respiratory depression in rats while preserving opioid-induced analgesia. Adopting a translational approach, we orally administered 1500 mg of CX717 to 16 male healthy volunteers in a placebo controlled double-blind study. Starting 100 min after CX717 or placebo intake, alfentanil was administered by computerized intravenous infusion targeting a plateau of effective alfentanil plasma concentrations of 100 ng/ml. One hour after start of opioid infusion, its effects were antagonized by intravenous injection of 1.6 mg of the classical opioid antidote naloxone. Respiration was quantified prior to drug administration (baseline), during alfentanil infusion and after naloxone administration by (i) counting the spontaneous respiratory frequency at rest and (ii) by employing hypercapnic challenge with CO2 rebreathing that assessed the expiratory volume at a carbon dioxide concentration in the breathable air of 55% (VE55). Pain was quantified at the same time points, immediately after assessment of respiratory parameters, by (i) measuring the tolerance to electrical stimuli (5 Hz sine increased by 0.2 mA/s from 0 to 20 mA and applied via two gold electrodes placed on the medial and lateral side of the mid-phalanx of the right middle finger) and (ii) by measuring the tolerance to heat (increased by 0.3°C/s from 32 to 52.5°C applied to a 3 x 3 cm2 skin area of the left volar forearm, after sensitization with 0.15 g capsaicin cream 0.1%). CX717 was tolerated by all subjects without side effects that would have required medical intervention. We observed that CX717 was approximately as effective as naloxone in reversing the opioid induced reduction of the respiratory frequency. Despite the presence of high plasma alfentanil concentrations, the respiratory frequency decreased only by 8.9 ± 22.4% when CX717 was pre-administered, which was comparable to the 7.0 ± 19.3% decrease observed after administration of naloxone. In contrast, after placebo pre-administration the respiratory rate decreased by 30.0 ± 21.3% (p=0.0054 for CX717 versus placebo). In agreement with this, periods of a very low respiratory frequency of <= 4 min-1 under alfentanil alone were shortened by ampakine pre-dosing by 52.9% (p=0.0182 for CX717 versus placebo). Furthermore, VE55 was decreased during alfentanil infusion by 55.9 ± 16.7% under placebo preadministration but only by 46.0 ± 18.1% under CX717 pre-administration (p=0.017 for CX717 versus placebo). Most importantly, in contrast to naloxone, CX717 had no effect on opioid induced analgesia. Alfentanil increased the pain tolerance to electrical stimuli by 68.7 ± 59.5% with placebo pre-administration. With CX717 pre-administration, the increase of the electrical pain tolerance was similar (54.6 ± 56.7%, p=0.1 for CX717 versus placebo). Similarly, alfentanil increased the heat pain tolerance threshold by 24.6 ± 10.0% with placebo pre-administration. Ampakine co-administration had also no effect on the increase of the heat pain tolerance of the capsaicin-sensitized skin (23.1 ± 8.3%, p=0.46 for CX717 versus placebo). The results of this study allow us to draw the conclusion, that opioid induced ventilatory depression can be selectively antagonized in humans by co-administering an ampakine. This is the first successful translation of a selective antagonism of opioidinduced respiratory depression from animal research into application in humans. Ampakines, namely CX717, thus are the first selective antidote for opioid-induced respiratory depression without loss of analgesia, available for the use in humans.
Atherosclerosis is accompanied by infiltration of macrophages to the intima of blood vessels. There they engulf oxLDL (oxidized low-density lipoproteins) and differentiate to foam cells. These cells are known as major promoters of atherosclerosis progression. In initial experiments I could demonstrate that foam cell formation caused a severe loss in the ability to produce IFNA (interferon A) in response to stimulation with the bacterial cell wall component LPS (lipopolysaccharide). Since IFNA is discussed to have anti-atherosclerotic potential and has the capability to induce immune tolerance, its inhibition in foam cells might promote the atherosclerotic process. For this reason the aim of my PhD project was to clarify the underlying molecular mechanisms that attenuate LPS-induced IFNA expression in foam cells. LPS activates TLR4 (Toll-like receptor 4) in macrophages. Downstream this receptor two distinct signaling pathways are activated, namely a MyD88 (myeloid differentiation primary response gene 88)-dependent and a TRIF (TIR-domain-containing adapter-inducing IFNA)-dependent one. Foam cell formation targeted the TRIF-dependent TLR4 signaling pathway, as seen by loss of IRF3 activation and IFNA expression inhibition, whereas MyD88-initiated NFBB (nuclear factor 'B-light-chain-enhancer' of activated B-cells) activation and subsequent TNF@ (tumor necrosis factor @) expression remained unaltered. The TRIF signaling cascade results in transactivation of the transcription factor IRF3 (interferon regulatory factor 3), the main activator of IFNA expression. This event demands IRF3 phosphorylation by TBK1 (TANK-binding kinase 1), whereas TBK1 needs to be recruited to TRAF3 (TNF receptor associated factor 3) by the scaffold protein TANK (TRAF family member-associated NFBB activator) for its activation. This work allowed to propose the following scheme: OxLDL utilizes SR-A1 (scavenger receptor A1) to activate IRAK4 (interleukin-1 receptor-associated kinase 4), IRAK1 and Pellino3. Active IRAK1 and Pellino3 associate with TRAF3 and Pellino3 promotes mono-ubiquitination of the adaptor molecule TANK. Mono-ubiquitination of TANK interrupts TBK1 recruitment to TRAF3 and thereby abrogates phosphorylation and transactivation of IRF3 as well as subsequent expression of IFNA. In this study I provide evidence for a negative regulatory role of Pellino3 for TRIF-dependent TLR4 signaling. This expands the current knowledge of the interplay between pathways downstream scavenger and Toll-like receptors. Due to the multifaceted roles of TLR4 signaling in pathology, the new TRIF-signaling inhibitor Pellino3 might be of importance as therapeutical target for disease intervention.
The role of peroxisome proliferator-activated receptor gamma during sepsis-induced lymphopenia
(2011)
Sepsis is one of the most common diseases on intensive care units all over the world and accounts there for the highest mortality rate. One of the hallmarks of sepsis is an accelerated T-cell apoptosis, resulting in a compromised immune state with the inability to eradicate pathogens. This promotes organ damage or even organ failure. A multiple organ dysfunction evolves, which often ends up in septic shock and death. Recently, it was shown that severe T-cell depletion correlates with sepsis mortality. When inhibiting T-cell apoptosis, an increased mouse survival was observed in experimental sepsis. ...
Langzeitbeobachtung der Therapie von Hämophilie A-Patienten mit einem humanen Faktor VIII-Konzentrat
(2019)
This doctoral thesis entitled “Long-term surveillance of the therapy of haemophilia A patients with a human plasma-derived factor VIII concentrate” was performed to assess the influence of the chronic long-term therapy with a human plasma-derived factor VIII concentrate in daily clinical practice on the health of haemophilia A patients.
Haemophilia A is a chronic disease, caused by a congenital deficiency of coagulation factor VIII, which requires life-long haemostatic treatment. The severity of bleedings, as the main clinical feature of haemophilia A, is generally correlated with the residual activity of coagulation factor VIII.
Until recently, factor VIII preparations, used to replace the deficient factor VIII, were the only treatment option for haemophilia A. Development of inhibitory antibodies against factor VIII is the most serious complication associated with the use of factor VIII products, rendering the administered factor VIII ineffective.
To date, all novel treatments still rely on some factor VIII replacement therapy. At least in the near future and probably for longer, (concomitant) therapy with factor VIII concentrates will continue to be necessary for treatment of haemophilia A, emphasising the continuous need for efficacy and safety data in terms of pharmacovigilance on factor VIII replacement therapy.
Medicines to treat haemophilia A, are authorised for use, when evidence of its efficacy and safety is limited to data of a small number of investigated patients during short-term observation periods of about six months, and thus have not been systematically assessed in all patient groups until marketing authorisation. Long-term efficacy and safety data from post-marketing surveillance are important to prove that a chronic treatment is efficacious and safe in the real-life setting by monitoring “real-life” patients of all age groups, rather than a carefully selected patient population. Medical and scientific analyses of such long-term data are crucial to detect, understand, and potentially prevent the harm resulting from (new) adverse drug reactions, including those, which only rarely occur and therefore are difficult to detect.
Therefore, data from two prospective surveillance studies investigating real-life therapies with the same human plasma derived factor VIII concentrate were combined and analysed retrospectively. It was hypothesised that the chronic long term therapy with a human plasma-derived factor VIII concentrate in daily clinical practice is effective, safe, and well tolerated with no unexpected adverse effect on the health of haemophilia A patients. It was the aim of this analysis to investigate the influence of the chronic long-term treatment with the factor VIII concentrate on the health of patients with severe as well as nonsevere haemophilia A including all age groups in a real-life setting. In addition, the influence of prophylactic factor VIII treatment or the switch to this regimen on the annual bleeding rate of all haemophilia A patients, and the long-term effects of this regimen on the patients’ annual bleeding rates were investigated.
Starting in 1998 until 2015, data of 1418 patient-years from 198 haemophilia A patients representing all age groups and haemophilia A severities were analysed. This study covered 18 years of documentation time with a mean observation period of more than seven years per patient. It is the longest study of a single factor VIII concentrate conducted so far, investigating the therapy of haemophilia A. The only observed side effects involved low incident factor VIII inhibitor formation in patients at risk (13 % of previously untreated patients, compared with usually about 30 %). Factor VIII inhibitor development was mainly transient, with low titers, and without clinical relevance. Any, even low frequent prophylaxis was found to be significantly better than on demand and had the greatest effect on the annual bleeding rate of patients, irrespective of their age or haemophilia A severity. Patients suffered during continuous prophylaxis from a very low bleeding rate (median 1.3 compared with 31.4 under on demand), down to no bleeding per year. Patients whose regimen changed to continuous prophylaxis benefitted most (median annual bleeding rate 1.1), irrespective of age or haemophilia A severity.
This analysis demonstrates that the chronic long-term therapy with the plasma-derived factor VIII concentrate in daily clinical practice is effective, safe, and well tolerated. Thus, data on efficacy and safety obtained during chronic long-term therapy with the human plasma-derived factor VIII concentrate reaffirm that there is no unexpected adverse effect on the health of haemophilia A patients.
These results support the therapeutic concept of a life-long prophylaxis of haemophilia A patients with a human plasma-derived factor VIII concentrate.